Filing Flows › Emergent BioSolutions (EBS) › How it makes money
How Emergent BioSolutions (EBS) makes money
Emergent BioSolutions (EBS) made $110M of revenue in the third quarter 2026 (Q3 2026), -52% from a year earlier. MCM Product sales brought in $59.4M (54%); Commercial Product sales brought in $43.5M (40%); All other revenue brought in $7.1M (6%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| MCM Product sales | $59.4M | 54.0% | -65% | -58% |
| Commercial Product sales | $43.5M | 39.5% | -17% | -42% |
| All other revenue | $7.1M | 6.5% | -49% | -48% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $110M | 100.0% |
| Operating cash flow | $100M | 91.0% |
| Free cash flow | $96.8M | 88.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $110M | -52% |
| Q2 2026 | $234M | +66% |
| Q1 2026 | $156M | -30% |
| Q4 2025 | $149M | -24% |
| Q3 2025 | $231M | -21% |
| Q2 2025 | $141M | -45% |
| Q1 2025 | $222M | -26% |
From Emergent BioSolutions' 10-Q filed Nov 3, 2026 (on EDGAR).
Questions
How does Emergent BioSolutions make money?
Emergent BioSolutions (EBS) made $110M of revenue in the third quarter 2026 (Q3 2026), -52% from a year earlier. MCM Product sales brought in $59.4M (54%); Commercial Product sales brought in $43.5M (40%); All other revenue brought in $7.1M (6%).
What is Emergent BioSolutions' biggest business?
MCM Product sales: $59.4M in the third quarter 2026, 54% of revenue, -58% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.